Evidence map›Paper›PMID 31174993›Full record

Trial reportThe lancet. Diabetes & endocrinology2019

Adjunctive liraglutide treatment in patients with persistent or recurrent type 2 diabetes after metabolic surgery (GRAVITAS): a randomised, double-blind, placebo-controlled trial.

Alexander Dimitri Miras, Belén Pérez-Pevida, Madhawi Aldhwayan, Anna Kamocka, Emma Rose McGlone, Werd Al-Najim, Harvinder Chahal, Rachel L Batterham, Barbara McGowan, Omar Khan and 6 more

Open access · greenAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in The lancet. Diabetes & endocrinology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 101 papers, 14 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
101citing papers in PubMed, 14 pooled it
14.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

101 citing papers in PubMed, 14 syntheses or guidelines pooled it, 172 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Guideline
  9. Pooled it
  10. Pooled it
  11. Obesity in South and Southeast Asia-A new consensus on care and management.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2023
    Guideline
  12. Pooled it
  13. Pooled it
  14. Guideline
  15. Trial
  16. Trial
  17. Trial
  18. Article
  19. Review
  20. Review

41 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 8 institutions in 2 countries.

Alexander Dimitri MirasDivision of Diabetes, Endocrinology and Metabolism, Department of Medicine, Imperial College London and Imperial College Healthcare NHS Trust, London, UK.
Belén Pérez-PevidaDivision of Diabetes, Endocrinology and Metabolism, Department of Medicine, Imperial College London and Imperial College Healthcare NHS Trust, London, UK.
Madhawi AldhwayanDivision of Diabetes, Endocrinology and Metabolism, Department of Medicine, Imperial College London and Imperial College Healthcare NHS Trust, London, UK.
Anna KamockaDivision of Diabetes, Endocrinology and Metabolism, Department of Medicine, Imperial College London and Imperial College Healthcare NHS Trust, London, UK.
Emma Rose McGloneDivision of Diabetes, Endocrinology and Metabolism, Department of Medicine, Imperial College London and Imperial College Healthcare NHS Trust, London, UK.
Werd Al-NajimDivision of Diabetes, Endocrinology and Metabolism, Department of Medicine, Imperial College London and Imperial College Healthcare NHS Trust, London, UK; Diabetes Complications Research Centre, Conway Institute, University College Dublin, Dublin, Ireland.
Harvinder ChahalDivision of Diabetes, Endocrinology and Metabolism, Department of Medicine, Imperial College London and Imperial College Healthcare NHS Trust, London, UK.
Rachel L BatterhamCentre for Obesity Research, Rayne Institute, Department of Medicine, University College London, London, UK; Bariatric Centre for Weight Management and Metabolic Surgery and National Institute for Health Research Biomedical Research Centre, University College London Hospital, London, UK.
Barbara McGowanDiabetes and Endocrinology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
Omar KhanSurgery, St George's University Hospitals NHS Trust, London, UK.
Veronica GreenerDiabetes and Endocrinology, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK.
Ahmed R AhmedDepartment of Surgery & Cancer, Imperial College London and Imperial College Healthcare NHS Trust, London, UK.
Aviva PetrieEastman Dental Institute, University College London, London, UK.
Samantha ScholtzDivision of Diabetes, Endocrinology and Metabolism, Department of Medicine, Imperial College London and Imperial College Healthcare NHS Trust, London, UK.
Stephen R BloomDivision of Diabetes, Endocrinology and Metabolism, Department of Medicine, Imperial College London and Imperial College Healthcare NHS Trust, London, UK.
Tricia M TanDivision of Diabetes, Endocrinology and Metabolism, Department of Medicine, Imperial College London and Imperial College Healthcare NHS Trust, London, UK. Electronic address: t.tan@imperial.ac.uk.
Imperial College Healthcare NHS Trust · GBImperial College London · GBChelsea and Westminster Hospital NHS Foundation Trust · GBGuy's and St Thomas' NHS Foundation Trust · GBRoyal London Hospital · GBSt George’s University Hospitals NHS Foundation Trust · GBUniversity College Dublin · IEUniversity College London · GB

Funding

Department of Health RP-2015-06-005Medical Research Council G0902002Medical Research Council MR/P01870X/1
6 · The paper itself

Abstract

backgroundMany patients with type 2 diabetes do not achieve sustained diabetes remission after metabolic (bariatric) surgery for the treatment of obesity. Liraglutide, a glucagon-like peptide-1 analogue, improves glycaemic control and reduces bodyweight in patients with type 2 diabetes. Our aim was to assess the safety and efficacy of liraglutide 1·8 mg in patients with persistent or recurrent type 2 diabetes after metabolic surgery.

methodsIn the GRAVITAS randomised double-blind, placebo-controlled trial, we enrolled adults who had undergone Roux-en-Y gastric bypass or vertical sleeve gastrectomy and had persistent or recurrent type 2 diabetes with HbA

findingsBetween Jan 29, 2016, and May 2, 2018, we assigned 80 patients to receive either liraglutide (n=53) or placebo (n=27). 71 (89%) participants completed the study and were included in the principal complete-cases analysis. In a multivariable linear regression analysis, with baseline HbA

interpretationThese findings support the use of adjunctive liraglutide treatment in patients with persistent or recurrent type 2 diabetes after metabolic surgery.

fundingJP Moulton Foundation.

Indexed as

Bariatric SurgeryAgedDiabetes Mellitus, Type 2Double-Blind MethodFemaleHumansHypoglycemic AgentsLiraglutideMaleMiddle AgedPostoperative ComplicationsHypoglycemic AgentsLiraglutide

Identifiers

PMID31174993
OpenAlexW2948337368

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.